Ascentage Pharma Group International
ascentage.cnWhat Do They Do?
Develops and sells drug treatments for cancer patients, including medicines for blood cancers.
20-F for FY2025, filed Apr 29, 2026We are a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of…View ↗
Our first lead asset, Olverembatinib, is a novel, third-generation tyrosine kinase inhibitor, or TKI. Olverembatinib was the first BCR-ABL1…View ↗
Our second lead asset, Lisaftoclax, is a novel Bcl-2 inhibitor that we are developing for the treatment of various hematological…View ↗
Loading...
